RxDoctor Payments Data

Amber Rupiper, PA

Physician Assistant · Des Moines, IANPI 1679189971

Payments from drug & device makers

$2,854in general payments, 2019–2025

Across 89 payments — averaging $32.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Teleflex LLC$472
  • Sumitomo Pharma America, Inc.$216
  • Myovant Sciences Inc.$128
  • Astellas Pharma US Inc$121
  • Genmab U.S., Inc.$119
  • plus $610 from 15 others

What the payments were for

  • Travel & lodging$55820%
  • Food & beverage$2,19677%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,854 in reported general payments places this provider in the 90th percentile of 1,140 physician assistant providers in Iowa.

See all physician assistant providers in Iowa

Medicare billing

Part B allowed, 2024
$9,267
Medicare patients
40
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron63$29,349
Potassium Citrate ErPotassium Citrate27$2,496
Trimethoprim33$1,577
Tolterodine Tartrate ErTolterodine Tartrate14$1,542
Tamsulosin Hcl95$1,278
Methenamine Hippurate20$1,073
Estradiol11$957
Finasteride58$831
Solifenacin Succinate13$800
NitrofurantoinNitrofurantoin Macrocrystal34$571
Oxybutynin Chloride ErOxybutynin Chloride16$179
Cephalexin14$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$121$29,34963 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,140 physician assistant providers in Iowa.

Other physician assistant in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →